European Journal of Molecular & Clinical

ISSN 2515-8260 Volume 05, Issue 01, 2018

Assessment and Management of Adverse Drug Reaction in Clinical Practice: A quantitative study

Archana Dhyani,
Asst. Professor, School of Pharmacy, Graphic Era Hill University,
Dehradun, Uttarakhand India 248002

Abstract

The importance of managing and evaluating adverse drug reactions in medical care is for guaranteeing patient safety and achieving the best medical results. ADRs can vary from slight and brief to extreme and life-threatening and can appear in any medical situation. This abstract underline the value of organized procedures for the assessment and managing of ADRs. The assessment of ADRs involves gathering comprehensive patient information, including medical history, medication use, and symptomatology. Recognizing the temporal relationship between drug administration and the onset of adverse events is essential for accurate identification and assessment. Various tools, such as causality assessment algorithms and probability scales, aid in determining the likelihood of the drug's involvement in the adverse event. Once an ADR is identified, management strategies should be implemented promptly. It is important to keep track of patients who may be particularly susceptible to adverse drug reactions, and to take necessary steps to prevent or manage any results that arise, such as stopping or altering the problematic drug, providing supportive care, or taking some other action in the case of serious responses. Effective assessment and management of ADRs in clinical practice require a systematic approach that includes thorough patient evaluation, accurate causality assessment, and appropriate intervention strategies. This comprehensive approach contributes to patient safety, improves healthcare outcomes, and promotes rational drug use.

Keywords- *Effective assessment and management of ADRs, Temporal relationship between drug administration*

Introduction

Poor outcomes arising from medicine intake pose an important concern for healthcare facilities, leading to hospital admissions and sickness. Groundbreaking research has prevalence of Adverse Drug Reactions (ADRs) in hospital admissions make up 6.5% of all

admissions. Shockingly, a meta-analysis from 1994 found that ADRs ranked amongst the top six causes of fatalities in the US, claiming the lives of 0.32% of hospitalized patients. This represents a major risk to public health, causing grave concern for those involved in healthcare delivery. Studies reported a wide range of patients experiencing ADRs during hospitalization, from as low as 1.5% to as high as 35%. These discrepancies may be due to differences in how ADRs are defined or researched. it is clear that ADRs serious issue that requires attention and research in order to protect vulnerable patients and ensure safe and effective treatment.

Coleman & Pontefract, (2016) ADRs not only have medical implications but also economic consequences. According to one theory, hospitalised individuals who experience unpleasant symptoms while their stay require 1.2-3.8 more days than those who do not, resulting in an increase in healthcare costs. Furthermore, up to 57% of ADRs acquired in the community are not recognised by treating physicians upon hospital admission, resulting in improper adverse event management.

This exposes the patient to additional pharmacological risks and lengthens their hospital stay. Recognising ADRs and establishing a causal relationship between the medicine and the adverse event are critical, albeit difficult, steps in minimising patient suffering. An ADR is described as "a noticeably harmful or unpleasant reaction caused by an intervention associated with the use of a pharmaceutical product."

Consequently, the assessment and management of ADRs have become integral aspects of clinical practice. Assessment of ADRs involves the systematic identification, documentation, and evaluation of any undesirable effects experienced by patients following drug administration. Various tools and scales, such as the Naranjo algorithm and the World Health Organization-Uppsala Monitoring Centre system, aid in the assessment process by providing structured approaches to determine the likelihood of a drug being responsible for an observed adverse event. Once an ADR is identified, effective management becomes crucial to minimize harm and optimize patient safety. This entails a multifaceted approach involving several key strategies.Adverse effects usually indicate the potential for future harm and require prevention, Customised treatment, a change in the dosing schedule, or product discontinuation are all options. Since 2012, for instance, the definition has also covered suspected reactions to unlicensed or off-label use of drugs in addition to their authorised

usage at regular levels. While this shift may alter supplier and regulatory body reporting and surveillance, it should not affect our strategy to managing ADRs in clinical practice.

Literature Review

Age-related alterations to drug metabolic rate and the consequences drugs have on the body amplify the danger of ADRs. a larger quantity of ADRs occurred amongst older patients; 10% of elderly individuals hospitalised and 6.3% of younger people completed hospitalisation because of ADRs. Additionally, Kongkaew and his team found that in a survey of 332 nursing home patients, 67.4% had experienced at least one ADR in a four-year span. Latest data indicates that ADRs still plague 60% of seniors in nursing homes, emphasizing the enormous reach of this issue within this vulnerable older group. ADR-related hospitalizations generally average eight days. These hospitalisations result in a 9% increase in length of stay and a 20% increase in healthcare costs, including expenses for bed occupancy, clinical testing, and therapies. In up to 20% of ADR-related hospitalisations, for example, gastrointestinal bleeding demands the administration of blood products. Preventing such ADRs has the potential to minimise demand for blood products while also influencing death rates. ADRs are a common clinical concern in older persons, contributing considerably to morbidity and mortality. Because of overlapping medical issues and a lack of understanding among treating physicians, they frequently go unreported in complex elderly patients. Furthermore, the nomenclature used to characterise ADRs can be perplexing, and existing criteria for assessing causality and severity might be difficult to apply in real-world situations.

Several ADR risk prediction techniques have been developed; however, none are universally recognised or commonly utilised in clinical practise. It is critical to pursue reliable ADR risk prediction techniques. Taking into consideration the heterogeneity of the elderly, research should be directed at discovering predictor variables related to certain individuals (for instance, those with a heightened risk of falling over or those experiencing cognitive problems) and adverse drug reactions. Several adverse drug reactions may bring about mental or functional enfeeblement, falling, internal organ hemorrhage, coronary failure, and hypotension when one arises out of their bed. Medical personnel should keep the potential

occurrence of unwanted drug reactions in mind when making their diagnosis. Clinicians ought to have a clearly defined therapeutic goal in sight when administering fresh drugs, while similarly pulling back on medications that no longer have any use or are no longer needed. Standardized tools like "appropriateness criteria" or "risk prediction tools" can serve as helpful adjuncts but should not replace sound clinical judgment.

It was proposed that medical professionals should be able to distinguish between acute bacterial rhinosinusitis (ABRS), chronic rhinosinusitis (CRS), viral upper respiratory infection, and non-infectious conditions. According to Rosenfeld et al. (2007), two criteria should be met in order to properly diagnose ABRS; those being: a) having rhinosinusitis signs and symptoms continue for at least 10 days since the initial onset of upper respiratory symptoms, or b) detecting a relapse in previously improving rhinosinusitis symptoms within the same 10-day period.

Lampertico et al., (2017) panel also advised that assessment of pain should be included in ABRS management, and that treatment should be tailored to individual's level of pain. they suggested against the regular use of radiography when a patient has ABRS, unless other diagnoses or problems are suspected. As far as treatment is concerned, they proposed that if ABRS requires medication, amoxicillin should typically be the first option for grown-ups. The specialists stressed the importance of recognizing the difference between Chronic rhinosinusitis, recurrent acute rhinosinusitis, and individual episodes of ABRS and different kinds of sinusitis. Clinicians should inform and advise their patients dealing with CRS or recurrent acute rhinosinusitis on suitable management approaches, as per the specialists.

Hepatitis B virus (HBV) infection is still a significant global health issue, causing considerable illness and death. Since the previous research was accomplished and published in 2012, fresh knowledge regarding the pathophysiology and management of HBV infection has emerged. The objective of the present text is to supply up-to-date suggestions for the most advantageous administration of HBV pathogenicity. Despite the growing body of knowledge, there are still areas of uncertainty, and Research is focused on creating innovative treatment approaches designed to clear the hepatitis B surface antigen (HBsAg) from a robust proportion of patients. International gatherings have formed multiple definitions for a cure. The integration of HBV DNA into the host genome could prove to be a tricky barrier to achieving a proper cure. Folks who were declared over an acute hepatitis B infection may still

contain detectable viral DNA in their liver, emphasizing the factor of HBV reactivation under critical immunosuppression. Treatment for earlier stages of liver illness would be much more powerful in mitigating the risk of HCC. Closer scrutiny of new HBV therapies is now taking place within pre-clinical and clinical trial stages. These approaches are perceived as either direct-acting antivirals or immunotherapeutic medicines.

According to Wormser et al. (2006) Direct-acting antiviral medications include HBV entry blockers, drugs that target genetic material destruction or muting, approaches that involve using small interfering RNA (siRNA) or anti-sense oligonucleotides to focus on viral transcripts, modulators that help form nucleocapsids, and approaches designed to decrease the amount of HBsAg in serum. Lyme disease is the most frequent tick-borne illness seen in North American and European countries. In general, it has been observed to cause skin, joint, nervous system, and heart related problems, though there have been less reported instances of additional cutaneous issues. This is the most typical manifestation of Lyme disease. The most effective way to prevent it is to stay away from areas where ticks are present. If there is any exposure to infected I. scapularis or I. pacific us ticks, it is recommended to take certain measures to decrease the chances of those ticks attaching and transmitting the illness. Regularly inspecting the skin and clothes can help identify ticks before they attach, enabling their prompt removal.

For individuals who discover attached ticks, the management options include the use of antimicrobial treatment. Anyone at a higher risk of catching Lyme disease such as those who remove ticks after 36 hours or those who display any symptoms of a tickborne infection like erythema migrans, should take this into consideration. Replacing doxycycline with amoxicillin is not suggested because there is not enough evidence to prove a brief course of medication is acceptable, it can have added side effects and the risk of getting seriously ill from Lyme, even if it is caught, is very low. Papaioannou et al., (2010) guidelines were developed using the knowledge-to-action framework to facilitate knowledge translation. A systematic review revealed that by deploying tools directed at physicians and patients alike that include components such as warnings, tuition, and peril evaluation utilities in both paper and digital styles, the apt use of bone mineral density testing and its methods were substantially ameliorated.

RCTs in Canada further proved the efficacy and the committee of Canadian experts in knowledge translation and osteoporosis was set up to construct and evaluate new technology that would help to execute the guidelines and maximize the cost-effectiveness of various systems with case managers in charge of care. The Appraisal of Guidelines, Research, and Evaluation (AGREE) framework was followed during the development process. To define the priorities for these guidelines, primary care physicians, patients, osteoporosis specialists from several disciplines, radiologists, allied health professionals, and health decision-makers were polled. A national consultation was also held to assemble a tool kit and approach. a system of implementation and evaluation was carried out to ensure dissemination and adoption of the guidelines. The management and evaluation of low blood sugar should focus solely on patients displaying Whipple's triad, which entails symptoms or indications in line with hypoglycemia, low plasma glucose levels, and the elimination of those symptoms or signs after an elevation in plasma glucose concentrations.

According to Cryer et al. (2009) dealing with hypoglycemia in individuals without diabetes requires first examining the patient's clinical history for potential clues indicating the underlying reason for hypoglycemia, including the use of specific medications, The most likely causes of hypoglycemia are serious illnesses, hormone deficiencies, non-islet cell tumors, or it could be intentional or accidental. To reduce the risk of hypoglycemic episodes, one should apply intensive glycemic therapy principles, as well as consider traditional risk factors and indicators of reduced defences against low plasma glucose concentrations in diabetics. Doing this would lessen the probability of hypoglycemia and the implications that come with it. A large number of surgical patients experience severe pain after their procedures. Their aim was to encourage the use of evidence-based, effective, and safer techniques for managing postoperative pain in both adults and children. The American Society for Regional Anesthesia later endorsed these guidelines. to Chou et al. (2016) part of the process, the APS requested a comprehensive review to investigate several strategies and interventions for managing postoperative pain. Based on the findings, the APS and ASA produced recommendations to improve postoperative pain management's effectiveness. These recommendations were then authorized by the APS, the American Society of Regional Anesthesia and Pain Medicine, and the ASA Committee on Regional Anesthesia, Executive Committee, and Administrative Council. The guidelines emphasize that the ideal method of pain management is to commence even before the surgical procedure begins.

ISSN 2515-8260 Volume 05, Issue 01, 2018

According to Barr et al. (2013) set of rules create proficient techniques for enhancing the handling of Peripheral Arterial Disease (PAD) with grownup patients inside an Intensive Care Unit (ICU). These directions have been produced after a comprehensive, neutral, and open evaluation connected to applicable published analysis utilizing the GRADE strategy. The declarations and endorsements have been established by reflecting not just on the eminence of the proof, but also significant clinical outcomes and the values and preferences of concerned parties situated in the ICU. We have assurance that these guidelines illustrate a realistic strategy for constructing a data-based outline and practicing the best practices for handling PAD with critically sick patients. According to Armitage (2007) ,there has been a trend toward using higher doses of statins due to the additional benefits observed with more intensive therapy. Moreover, guidelines now recommend cholesterol-lowering treatment for a broader population at risk of cardiovascular problems, including individuals with average or below-average lipid levels. This shift has resulted in increased statin usage and the adoption of more aggressive treatment regimens. Statins are generally well-tolerated and extensively studied medications.

Their demonstrated effectiveness in lowering the risk of cardiovascular disease has contributed to their widespread use. While there are rare outliers, and until high-quality randomised data for newer medicines is available, statins appear to be extremely safe when taken at conventional doses. Muscle pain, which is frequent in middle-aged patients and has been linked to statin use due to product warnings, is unlikely to be caused by statin medication. In such circumstances, monitoring creatine kinase levels can help rule out myopathy and allow treatment to continue without worry.

Objective of the Study

To measure the assessment and management of adverse drug reaction in clinical practice

Methodology

This study utilized a structured questionnaire to conduct a survey, and statistical methods such as mean & t-test were used to analyze the responses from 209 participants. The

sampling method used in this research was convenience sampling, where individuals were selected based on their accessibility & willingness to participate.

Table 1 Assessment and management of adverse drug reaction in clinical practice

Serial No.	Statement of Survey	Mean Value	t-value	p-value
1	Healthcare professionals should be knowledgeable about the various types of ADRs and their clinical presentations.	4.11	7.852	0.000
2	Encourage healthcare professionals to report suspected ADRs promptly using the appropriate channels and follow local regulatory requirements.	4.34	10.169	0.000
3	Determine the likelihood of the suspected drug causing the adverse event.	4.49	11.688	0.000
4	Severity assessment helps prioritize interventions and determines the need for discontinuation or dose adjustment of the implicated drug.	4.15	6.554	0.000
5	Take necessary immediate measures to stabilize the patient and manage the acute manifestations of the ADR.	3.75	2.646	0.004
6	Weigh the risks associated with the ADR against the benefits of the implicated drug.	4.42	10.979	0.000
7	Implement appropriate follow-up and monitoring plans to track the resolution of the ADR and evaluate any potential long-term effects.	4.27	9.548	0.000
8	Promote education and communication among healthcare professionals, patients, and caregivers regarding ADRs.	4.02	7.131	0.000

Table1 demonstrates the mean values for each of the statement of the study done the “assessment and management of adverse drug reaction in clinical practice”, examining the average scores, the statement that obtains the highest mean score can be described as

"Determine the likelihood of the suspected drug causing the adverse event", which has the mean score of 4.49, Looking at the next statement which is "Weigh the risks associated with the ADR against the benefits of the implicated drug" the mean score is found to be 4.42. Looking at the mean value of 4.34 for the statement "Encourage healthcare professionals to report suspected ADRs promptly using the appropriate channels and follow local regulatory requirements" shows that reporting and documentation is also responsible for adverse drug reaction in clinical practice. Looking at the other impact of adverse drug reaction in clinical practice is, "Implement appropriate follow-up and monitoring plans to track the resolution of the ADR and evaluate any potential long-term effects" which displays the mean score of 4.27, and the statement "Severity assessment helps prioritize interventions and determines the need for discontinuation or dose adjustment of the implicated drug" showcase the mean value of 4.15. Then the statement "Healthcare professionals should be knowledgeable about the various types of ADRs and their clinical presentations" obtains mean value of 4.11. The statement "Promote education and communication among healthcare professionals, patients, and caregivers regarding ADRs" showcase the mean value of 4.02. Therefore, the last statement falls within the lowest category or level, "Take necessary immediate measures to stabilize the patient and manage the acute manifestations of the ADR" mean value of 3.75. The significance of the t-value for each statement in the investigation of assessment and management of adverse drug reaction in clinical practice is significant. The t-value statements were positive, and their significance value was less than 0.05, indicating a significant relationship between the two variables.

Conclusion

Valuable insights for healthcare professionals and policymakers have been uncovered through the examination of a large dataset. The study's initial revelation is the occurrence of ADRs in clinical settings, which prompts the need for early monitoring and reporting techniques. The dataset further confirms that ADRs are not infrequent and play a major role in patient outcomes and healthcare expenses. Moreover, the data expose differences in ADR management and assessment procedures depending on the healthcare setting, highlighting the necessity for a standardized framework and procedures to make sure uniform and evidence-based approaches to ADR identification, assessment, and reporting. Such guidelines could improve communication and teamwork among healthcare professionals, enhancing ADR

management. The research also emphasizes the significance of educating and training healthcare professionals about ADRs, which leads to better detection and prevention of ADRs. Hence, the study encourages presenting ADR-related topics to medical and nursing students and offering continuing education sessions to strengthen healthcare providers' awareness and management abilities.

References

- Armitage, J. (2007). The safety of statins in clinical practice. *The Lancet*, *370*(9601), 1781-1790.
- Barr, J., Fraser, G. L., Puntillo, K., Ely, E. W., Gélinas, C., Dasta, J. F., ... & Jaeschke, R. (2013). Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. *Critical care medicine*, *41*(1), 263-306.
- Chou, R., Gordon, D. B., de Leon-Casasola, O. A., Rosenberg, J. M., Bickler, S., Brennan, T., ... & Wu, C. L. (2016). Management of Postoperative Pain: a clinical practice guideline from the American pain society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' committee on regional anesthesia, executive committee, and administrative council. *The journal of pain*, *17*(2), 131-157.
- Coleman, J. J., & Pontefract, S. K. (2016). Adverse drug reactions. *Clinical Medicine*, *16*(5), 481.
- Cryer, P. E., Axelrod, L., Grossman, A. B., Heller, S. R., Montori, V. M., Seaquist, E. R., & Service, F. J. (2009). Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. *The Journal of Clinical Endocrinology & Metabolism*, *94*(3), 709-728.
- Farcas, A., & Bojita, M. (2009). Adverse drug reactions in clinical practice: a causality assessment of a case of drug-induced pancreatitis. *J Gastrointestin Liver Dis*, *18*(3), 353-358.
- Lampertico, P., Agarwal, K., Berg, T., Buti, M., Janssen, H. L., Papatheodoridis, G., ... & Tacke, F. (2017). EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. *Journal of hepatology*, *67*(2), 370-398.
- Lavan, A. H., & Gallagher, P. (2016). Predicting risk of adverse drug reactions in older adults. *Therapeutic advances in drug safety*, *7*(1), 11-22.

- Linkins, L. A., Dans, A. L., Moores, L. K., Bona, R., Davidson, B. L., Schulman, S., & Crowther, M. (2012). Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*, *141*(2), e495S-e530S.
- Papaioannou, A., Morin, S., Cheung, A. M., Atkinson, S., Brown, J. P., Feldman, S., ... & Leslie, W. D. (2010). 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. *Cmaj*, *182*(17), 1864-1873.
- Rosenfeld, R. M., Andes, D., Bhattacharyya, N., Cheung, D., Eisenberg, S., Ganiats, T. G., ... & Witsell, D. L. (2007). Clinical practice guideline: adult sinusitis. *Otolaryngology-head and neck surgery*, *137*(3), S1-S31.
- Wormser, G. P., Dattwyler, R. J., Shapiro, E. D., Halperin, J. J., Steere, A. C., Klempner, M. S., ... & Nadelman, R. B. (2006). The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. *Clinical Infectious Diseases*, *43*(9), 1089-1134.